AAV empty full analysis data
Example viral protein egrams
Example DNA egrams
Revvity’s LabChip AAV empty full solution
To meet individual laboratories’ needs, the LabChip AAV Empty/Full Solution is provided in bundles.
AAV Bundles |
---|
LabChip® AAV Empty/Full Reagents bundle + LabChip® AAV Empty/Full Chip bundle |
Or the components can be ordered separately:
AAV DNA Analysis | AAV Protein Analysis |
---|---|
LabChip® AAV DNA Analysis Kit LabChip® AAV DNA Chip LabChip® AAV8 standard |
LabChip® AAV Pico Protein Analysis kit LabChip® AAV Protein Analysis Chip LabChip® AAV8 standard |
Improve the efficiency of your protein development & manufacturing workflows
The LabChip GXII Touch characterization system provides a complete solution for reproducible quantitation, molecular weight sizing and percent purity analysis of protein samples. Learn how it can improve the efficiency of your protein characterization workflows.
Kit Specs
Requirement | Specification |
---|---|
Minimum Sample Volume Input Minimum AAV Sample Concentration AAV Sample Buffer Empty:Full Value Linearity Protein Assay Sensitivity ssDNA Assay Sensitivity Samples per chip preparation |
10 μL (5 uL + 5 uL) 1E12 VP/mL (or 1E12GC/mL for high population of empty AAV) PBS + (0.01% Tween 20 or 0.001% Pluronic) 0.95 5 ng/μL 250 pg/μL 24 |
Why are AAV particles being investigated for therapeutic use in gene therapy solutions?
Adeno-associated virus (AAV) particles are intensively being investigated for therapeutic use in gene therapy due to low immunogenicity and ability for long-term gene expression in vivo.
What is an AAV viral vector?
The AAV viral vector is comprised of a protein capsid with encapsulated ssDNA. The protein capsid is composed of three capsid proteins VP1, VP2 and VP3 with theoretical expected ratio of 1:1:10 respectively. The proteins are packaged into a stable icosahedral structure with diameter ~25 nm.
The encapsulated ssDNA is typically up to ~4.8 kb and are the therapeutic payloads that are critical to treating various diseases. During development, testing strategies for the viral protein stoichiometry, capsid product purity, and ssDNA loading efficacy are used to monitor and assess AAV efficacy.
How is the AAV loading efficiency determined?
The loading efficacy is observed as the percentage of capsids containing ssDNA (full capsids).
What are ineffective AAV capsids?
Ineffective capsids may contain no ssDNA (empty capsids) or DNA that is lower molecular weight (partial filled capsids).